The Study Of Sentinel Lymph Node Biopsy (SLNB) To Perform Axillary Lymph Node Dissection (ALND) In Early Breast Cancer

Objective:Axillary lymph node dissection (ALND) is routinely performed during surgery for breast cancer, but ALND could not increase survival rate of early breast cancer patients existing obvious complications. Recently, replacing ALND with sentinel lymph node biopsy (SLNB) has become a hot spot in early breast cancer research. This research aimed to study the feasibility of sentinel lymph node biopsy (SLNB) to perform axillary lymph node dissection (ALND) in early breast cancer. Methods:From July 2009 to July 2010,46 patients with early breast cancer form tumor hospital of Xinjiang medical university used 99mTc-SC and methylene blue to detect and dissect sentinel lymph node, and followed by the axillary lymph node dissection (ALND). All of the SLN and nSLN were evaluated and compared by pathologically (HE) after the operation. Results:SLN were successfully identified in 44 of 46 patients. Success rates were 95.65%. The number of SLN in every patient ranged from 1 to 8, and the total number of detected SLN was 137. The number of SLN was 3.11 in every case averagely. The cases of positive SLN were 19 of 44 patients, and the positive rate was 43.18%. The one cases of false negative were found in the group. The false negative rate was 5.00%. The accuracy and sensitivity rate of SLNB to predict axillary lymph node status were 97.73% and 95.00%. Conclusion: The sentinel lymph node biopsy can predict situation of axillary lymph node accurately and make the most of the early breast cancer patients from axillary lymph node dissection, worthing extending in the clinical.